Pharmadrug Inc.
PHRX
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -91.31% | -103.15% | -69.27% | -89.33% | 99.93% |
| Depreciation & Amortization | -5.38% | -53.37% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -90.15% | -87.77% | -72.17% | -99.16% | 126.43% |
| Operating Income | 90.15% | 87.77% | 72.17% | 99.16% | -126.43% |
| Income Before Tax | 79.67% | 99.95% | 40.68% | 66.35% | -203.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 79.67% | 99.94% | 40.68% | 66.35% | -203.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -63.91% | 27.17% | -- | -- | -- |
| Net Income | 81.06% | 100.58% | 40.68% | 66.35% | -178.82% |
| EBIT | 90.15% | 87.77% | 72.17% | 99.16% | -126.43% |
| EBITDA | 92.62% | 89.38% | 78.72% | 103.74% | -123.41% |
| EPS Basic | 84.62% | 100.41% | 70.45% | 83.87% | -50.00% |
| Normalized Basic EPS | 82.61% | 102.00% | 66.67% | 78.13% | 11.54% |
| EPS Diluted | 84.62% | 100.41% | 70.45% | 83.87% | -30.00% |
| Normalized Diluted EPS | 82.61% | 102.00% | 66.67% | 78.13% | 11.54% |
| Average Basic Shares Outstanding | 13.54% | 40.46% | 104.99% | 97.60% | 86.82% |
| Average Diluted Shares Outstanding | 13.54% | 40.46% | 104.99% | 97.60% | 86.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |